Clinical Trials Logo

Secondary Hyperparathyroidism clinical trials

View clinical trials related to Secondary Hyperparathyroidism.

Filter by:

NCT ID: NCT00891813 Completed - Hemodialysis Clinical Trials

Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose

Start date: May 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study is to observe the effectiveness and safety of the use of a low initial dose regime (iPTH/100) in chronic kidney disease patients with secondary hyperparathyroidism (PTH>300pg/mL) and that require dialysis at least 3 times per week.

NCT ID: NCT00888069 Completed - Clinical trials for Chronic Kidney Disease

Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects

Start date: May 2009
Phase: Phase 1
Study type: Interventional

This study will investigate how the levels of a single dose of CTAP101 changes in the body over time (pharmacokinetics, PK) and how CTAP101 affects other mineral and hormonal balances (pharmacodynamics, PD) in patients with Stage 3 or 4 chronic kidney disease (CKD) with vitamin D insufficiency and secondary hyperparathyroidism (SHPT).

NCT ID: NCT00828347 Completed - Clinical trials for Secondary Hyperparathyroidism

Maintenance Vitamin D Therapy for Secondary Hyperparathyroidism (2HPT)

Start date: January 2008
Phase: N/A
Study type: Interventional

There are still no established protocols for maintenance therapy with intravenous or oral vitamin D preparations after the iPTH target has been achieved. Therefore, the present study compared the efficacy of two maintenance therapy protocols, i.e., oral administration of alfacalcidol (an oral vitamin D preparation) at a dose of 1.0 ug/day (higher-dose group) or at a dose of 0.25 ug/day (lower-dose group), in patients with secondary hyperparathyroidism who responded to initial maxacalcitol therapy, resulting in the control of iPTH to < 150 pg/mL.

NCT ID: NCT00823303 Completed - Clinical trials for Chronic Kidney Disease

Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)

PACE
Start date: February 2009
Phase: Phase 4
Study type: Interventional

Secondary Hyperparathyroidism (SHPT) occurs in many patients with kidney disease and leads to bone disease. Active forms of vitamin D, calcitriol and paricalcitol, treat SHPT, but may have different effects on blood calcium. This study will randomize patients with SHPT and stage 3 or 4 CKD to treatment with calcitriol or paricalcitol, and monitor patients for the incidence of high blood calcium, and effectiveness of SHPT treatment.

NCT ID: NCT00803712 Completed - Clinical trials for Chronic Kidney Disease

20070360 Incident Dialysis

Start date: February 1, 2009
Phase: Phase 4
Study type: Interventional

Randomized Trial to Evaluate the Efficacy and Safety of Cinacalcet Treatment in Combination with Low Dose Vitamin D for the Treatment of Subjects with Secondary Hyperparathyroidism (SHPT) Recently Initiating Hemodialysis

NCT ID: NCT00792857 Completed - Clinical trials for Chronic Kidney Disease

Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)

Start date: November 2008
Phase: Phase 1
Study type: Interventional

This study will compare CTAP201 with Doxercalciferol in patients with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT), undergoing regular hemodialysis, at different dose strengths. This study will also investigate the levels of CTAP201 in the body over time and determine the safety of CTAP201.

NCT ID: NCT00754442 Completed - Clinical trials for Secondary Hyperparathyroidism

Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism

1hydroxylase
Start date: February 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if a reduction in the enzyme 1-hydroxylase, which activates Vitamin D, is the cause of overactivity of the parathyroid glands (called secondary hyperparathyroidism - normal blood calcium and elevated parathyroid hormone) in a selected group of young patients with normal kidney function.

NCT ID: NCT00742716 Completed - Clinical trials for Chronic Kidney Disease

Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease

Start date: October 2008
Phase: Phase 2
Study type: Interventional

This study will investigate the levels of CTA018 in the body over time (pharmacokinetics, PK) in patients with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT), undergoing regular hemodialysis. This study will also investigate the safety and effects of different strengths of CTA018, on parathyroid hormone (PTH) levels.

NCT ID: NCT00701805 Completed - Hemodialysis Clinical Trials

Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD)

Start date: July 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the long-term safety of paricalcitol injection. Subjects will administer clinical supplies 3 times a week, 40 weeks at dialysis session in dose-titration manner, following 12 weeks of treatment in the dose-response study, M10-309 (NCT00667576).

NCT ID: NCT00667576 Completed - Clinical trials for Secondary Hyperparathyroidism

Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis

Start date: April 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study was to investigate the initial dose and dose adjustment range for paricalcitol injection in patients with chronic kidney disease on hemodialysis who have secondary hyperparathyroidism.